PKI

PerkinElmer
NYSE

Real-time Quotes | Nasdaq Last Sale

93.41
+0.91
+0.98%
After Hours: 93.41 0 0.00% 16:00 05/22 EDT
OPEN
92.95
PREV CLOSE
92.50
HIGH
93.65
LOW
92.34
VOLUME
474.59K
TURNOVER
--
52 WEEK HIGH
102.46
52 WEEK LOW
62.91
MARKET CAP
10.40B
P/E (TTM)
45.79
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PKI stock price target is 98.83 with a high estimate of 110.00 and a low estimate of 85.00.

EPS

PKI News

More
PerkinElmer to Present at Jefferies Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.
Business Wire · 5d ago
PerkinElmer faces probe over alleged Medicare fraud - Reuters
Seeking Alpha - Article · 05/18 14:00
PerkinElmer denies Reuters report that it is being investigated in a Medicare fraud case
PerkinElmer Inc. said Monday that it has not received any information, and is not aware of any wrongdoing, as implied by a Reuters report. The diagnostics and health services company also said it did not have any information that it or any of its personnel ar
MarketWatch · 05/18 13:44
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and
Business Wire · 05/18 13:28
Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources
Medical diagnostic firm PerkinElmer Inc <PKI.N> faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents revie
Reuters · 05/18 11:17
PerkinElmer, Inc. -- Moody's announces completion of a periodic review of ratings of PerkinElmer, Inc.
Moody's · 05/15 20:04
PerkinElmer: The Market Completely Missed The Transformation
Seeking Alpha - Article · 05/07 20:32
UBS Maintains Neutral on PerkinElmer, Raises Price Target to $96
UBS maintains PerkinElmer (NYSE:PKI) with a Neutral and raises the price target from $95 to $96.
Benzinga · 05/07 16:19

Industry

Advanced Medical Equipment & Technology
+1.36%
Healthcare Equipment & Supplies
+1.09%

Hot Stocks

Symbol
Price
%Change

About PKI

PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.
More

Webull offers kinds of PerkinElmer, Inc. stock information, including NYSE:PKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PKI stock news, and many more online research tools to help you make informed decisions.